Mara Y Roth1, Grace Shih2, Niloufar Ilani3, Christina Wang3, Stephanie T Page4, William J Bremner4, Ronald S Swerdloff3, Regine Sitruk-Ware5, Diana L Blithe6, John K Amory4. 1. University of Washington, Department of Medicine and Center for Research in Reproduction and Contraception. Electronic address: mylang@u.washington.edu. 2. University of Washington, Department of Family Medicine. 3. Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Department of Medicine, Torrance, CA. 4. University of Washington, Department of Medicine and Center for Research in Reproduction and Contraception. 5. Center for Biomedical Research, Population Council, New York City, NY. 6. Contraceptive Discovery and Development Branch, NICHD, Bethesda, MD.
Abstract
OBJECTIVE: Fifty percent of pregnancies in the United States are unintended despite numerous contraceptive methods available to women. The only male contraceptive methods, vasectomy and condoms, are used by 10% and 16% of couples, respectively. Prior studies have shown efficacy of male hormonal contraceptives in development, but few have evaluated patient acceptability and potential use if commercially available. The objective of this study is to determine if a transdermal gel-based male hormonal contraceptive regimen, containing testosterone and Nestorone® gels, would be acceptable to study participants as a primary contraceptive method. STUDY DESIGN: As part of a three-arm, 6-month, double-blind, randomized controlled trial of testosterone and nestorone gels at two academic medical centers, subjects completed a questionnaire to assess the acceptability of the regimen. Of the 99 men randomized, 79 provided data for analysis. RESULTS: Overall, 56% (44/79) of men were satisfied or extremely satisfied with this gel-based method of contraception, and 51% (40/79) reported that they would recommend this method to others. One third of subjects (26/79) reported that they would use this as their primary method of contraception if it were commercially available today. However, men with concerns about sexually transmitted disease were significantly less satisfied than men without such concerns (p=0.03). CONCLUSIONS: A majority of the men who volunteered to participate in this trial of an experimental male hormonal contraceptive were satisfied with this transdermal male hormonal contraceptive. If commercially available, a combination of topical nesterone and testosterone gels could provide a reversible, effective method of contraception that is appealing to men. IMPLICATIONS: A substantial portion of men report they would use this transdermal male contraceptive regimen if commercially available. This method would provide a novel, reversible method of contraception for men, whose current choices are limited to condoms and vasectomy.
RCT Entities:
OBJECTIVE: Fifty percent of pregnancies in the United States are unintended despite numerous contraceptive methods available to women. The only male contraceptive methods, vasectomy and condoms, are used by 10% and 16% of couples, respectively. Prior studies have shown efficacy of male hormonal contraceptives in development, but few have evaluated patient acceptability and potential use if commercially available. The objective of this study is to determine if a transdermal gel-based male hormonal contraceptive regimen, containing testosterone and Nestorone® gels, would be acceptable to study participants as a primary contraceptive method. STUDY DESIGN: As part of a three-arm, 6-month, double-blind, randomized controlled trial of testosterone and nestorone gels at two academic medical centers, subjects completed a questionnaire to assess the acceptability of the regimen. Of the 99 men randomized, 79 provided data for analysis. RESULTS: Overall, 56% (44/79) of men were satisfied or extremely satisfied with this gel-based method of contraception, and 51% (40/79) reported that they would recommend this method to others. One third of subjects (26/79) reported that they would use this as their primary method of contraception if it were commercially available today. However, men with concerns about sexually transmitted disease were significantly less satisfied than men without such concerns (p=0.03). CONCLUSIONS: A majority of the men who volunteered to participate in this trial of an experimental male hormonal contraceptive were satisfied with this transdermal male hormonal contraceptive. If commercially available, a combination of topical nesterone and testosterone gels could provide a reversible, effective method of contraception that is appealing to men. IMPLICATIONS: A substantial portion of men report they would use this transdermal male contraceptive regimen if commercially available. This method would provide a novel, reversible method of contraception for men, whose current choices are limited to condoms and vasectomy.
Authors: M Y Roth; N Ilani; C Wang; S T Page; W J Bremner; R S Swerdloff; C Dart; R Sitruk-Ware; N Kumar; D Blithe; J K Amory Journal: Andrology Date: 2013-09-30 Impact factor: 3.842
Authors: M Cristina Meriggiola; S Cerpolini; W J Bremner; M T Mbizvo; K M Vogelsong; G Martorana; G Pelusi Journal: Hum Reprod Date: 2006-05-26 Impact factor: 6.918
Authors: John K Amory; Stephanie T Page; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner Journal: Contraception Date: 2007-01-16 Impact factor: 3.375
Authors: J Bradley Layton; Dongmei Li; Christoph R Meier; Julie L Sharpless; Til Stürmer; Susan S Jick; M Alan Brookhart Journal: J Clin Endocrinol Metab Date: 2014-01-01 Impact factor: 5.958
Authors: Vahid Mahabadi; John K Amory; Ronald S Swerdloff; William J Bremner; Stephanie T Page; Regine Sitruk-Ware; Peter D Christensen; Narender Kumar; Yun-Yen Tsong; Diana Blithe; Christina Wang Journal: J Clin Endocrinol Metab Date: 2009-04-14 Impact factor: 5.958
Authors: Peter Y Liu; Ronald S Swerdloff; Bradley D Anawalt; Richard A Anderson; William J Bremner; Joerg Elliesen; Yi-Qun Gu; Wendy M Kersemaekers; Robert I McLachlan; M Cristina Meriggiola; Eberhard Nieschlag; Regine Sitruk-Ware; Kirsten Vogelsong; Xing-Hai Wang; Frederick C W Wu; Michael Zitzmann; David J Handelsman; Christina Wang Journal: J Clin Endocrinol Metab Date: 2008-02-26 Impact factor: 5.958
Authors: Niloufar Ilani; Mara Y Roth; John K Amory; Ronald S Swerdloff; Clint Dart; Stephanie T Page; William J Bremner; Regine Sitruk-Ware; Narender Kumar; Diana L Blithe; Christina Wang Journal: J Clin Endocrinol Metab Date: 2012-07-12 Impact factor: 5.958
Authors: B D Anawalt; M Y Roth; J Ceponis; V Surampudi; J K Amory; R S Swerdloff; P Y Liu; C Dart; W J Bremner; R Sitruk-Ware; N Kumar; D L Blithe; S T Page; C Wang Journal: Andrology Date: 2019-04-10 Impact factor: 3.842